{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:17Z","timestamp":1794047477161,"version":"4.8.0"},"reference-count":37,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy causes serious side effects including cytokine release syndrome (CRS). CRS-related coagulopathy is associated with hypofibrinogenemia that has up to now been considered the result of disseminated intravascular coagulation (DIC) and liver dysfunction. We investigated the incidence and risk factors for hypofibrinogenemia in 41 consecutive adult patients with hematologic malignancies (median age 69 years, range 38-83 years) receiving CAR T-cell therapy between January 2020 and May 2023 at the University Medical Center Regensburg. CRS occurred in 93% of patients and was accompanied by hypofibrinogenemia already from CRS grade 1. Yet DIC and liver dysfunction mainly occurred in severe CRS (\u2265 grade 3). After an initial increase during CRS, fibrinogen levels dropped after administration of tocilizumab in a dose-dependent manner (r = -0.44, P=0.004). In contrast, patients who did not receive tocilizumab had increased fibrinogen levels. Logistic regression analysis identified tocilizumab as an independent risk factor for hypofibrinogenemia (odds ratio = 486, P&lt;0.001). We thus hypothesize that fibrinogen synthesis in CRS is up-regulated in an interleukin-6-dependent acute phase reaction compensating for CRS-induced consumption of coagulation factors. Tocilizumab inhibits fibrinogen upregulation resulting in prolonged hypofibrinogenemia. These observations provide novel insights into the pathophysiology of hypofibrinogenemia following CAR T-cell therapy, and emphasize the need for close fibrinogen monitoring after tocilizumab treatment of CRS.<\/jats:p>","DOI":"10.3324\/haematol.2023.284564","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T05:35:49Z","timestamp":1711604149000},"page":"2969-2977","source":"Crossref","is-referenced-by-count":23,"title":["Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies"],"prefix":"10.3324","volume":"109","author":[{"given":"Markus","family":"Perl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Herfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis C.","family":"Harrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"H\u00f6pting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Schweiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sterz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Kn\u00f6dler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Heimerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Hansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Poeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Edinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias A.","family":"Fante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"66007","doi-asserted-by":"crossref","unstructured":"Locke FL, Miklos DB, Jacobson CA. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022; 386(7):640-654.","DOI":"10.1056\/NEJMoa2116133"},{"key":"66008","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Svoboda J, Chong EA. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017; 377(26):2545-2554.","DOI":"10.1056\/NEJMoa1708566"},{"key":"66009","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD, Shah N. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8):705-716.","DOI":"10.1056\/NEJMoa2024850"},{"key":"66010","doi-asserted-by":"crossref","unstructured":"Shah BD, Ghobadi A, Oluwole OO. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; 398(10299):491-502.","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"66011","doi-asserted-by":"crossref","unstructured":"Umut \u00d6, Gottschlich A, Endres S, Kobold S. CAR T cell therapy in solid tumors: a short review. Memo. 2021; 14(2):143-149.","DOI":"10.1007\/s12254-021-00703-7"},{"key":"66012","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398(10297):314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"66013","doi-asserted-by":"crossref","unstructured":"Iacoboni G, Rejeski K, Villacampa G. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022; 6(12):3606-3610.","DOI":"10.1182\/bloodadvances.2021006922"},{"key":"66014","doi-asserted-by":"crossref","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022; 22(2):85-96.","DOI":"10.1038\/s41577-021-00547-6"},{"key":"66015","doi-asserted-by":"crossref","unstructured":"Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007; 7(10):803-815.","DOI":"10.1038\/nri2171"},{"key":"66016","doi-asserted-by":"crossref","unstructured":"Wang J, Doran J. The many faces of cytokine release syndrome-related coagulopathy. Clin Hematol Int. 2021; 3(1):3-12.","DOI":"10.2991\/chi.k.210117.001"},{"key":"66017","doi-asserted-by":"crossref","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019; 34:45-55.","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"66018","doi-asserted-by":"crossref","unstructured":"Lee DW, Gardner R, Porter DL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-195.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"66019","doi-asserted-by":"crossref","unstructured":"Hayden PJ, Roddie C, Bader P. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022; 33(3):259-275.","DOI":"10.1016\/j.annonc.2021.12.003"},{"key":"66020","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Tummala S, Kebriaei P. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15(1):47-62.","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"66021","doi-asserted-by":"crossref","unstructured":"Hines MR, Knight TE, McNerney KO. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023; 29(7):438.","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"66022","doi-asserted-by":"crossref","unstructured":"Fardet L, Galicier L, Lambotte O. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome: score for reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014; 66(9):2613-2620.","DOI":"10.1002\/art.38690"},{"key":"66023","doi-asserted-by":"crossref","unstructured":"Henter J-I, Horne A, Aric\u00f3 M. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007; 48(2):124-131.","DOI":"10.1002\/pbc.21039"},{"key":"66024","doi-asserted-by":"crossref","unstructured":"Jiang H, Liu L, Guo T. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019; 98(7):1721-1732.","DOI":"10.1007\/s00277-019-03685-z"},{"key":"66025","doi-asserted-by":"crossref","unstructured":"Maude SL, Frey N, Shaw PA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-1517.","DOI":"10.1056\/NEJMoa1407222"},{"key":"66026","doi-asserted-by":"crossref","unstructured":"Teachey DT, Lacey SF, Shaw PA. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016; 6(6):664-679.","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"66027","doi-asserted-by":"crossref","unstructured":"Buechner J, Grupp SA, Hiramatsu H. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 2021; 5(2):593-601.","DOI":"10.1182\/bloodadvances.2020002757"},{"key":"66028","doi-asserted-by":"crossref","unstructured":"Wang Y, Qi K, Cheng H. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transplant. 2020; 26(5):865-875.","DOI":"10.1016\/j.bbmt.2019.11.027"},{"key":"66029","doi-asserted-by":"crossref","unstructured":"Valade S, Azoulay E, Galicier L. Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis. Medicine (Baltimore). 2015; 94(40):e1692.","DOI":"10.1097\/MD.0000000000001692"},{"key":"66030","doi-asserted-by":"crossref","unstructured":"Hay KA, Hanafi L-A, Li D. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017; 130(21):2295-2306.","DOI":"10.1182\/blood-2017-06-793141"},{"key":"66031","doi-asserted-by":"crossref","unstructured":"Quan H, Li B, Couris CM. Updating and validating the Charlson Comorbidity Index and Score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011; 173(6):676-682.","DOI":"10.1093\/aje\/kwq433"},{"key":"66032","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4):625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"66033","doi-asserted-by":"crossref","unstructured":"Taylor FB, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001; 86(5):1327-1330.","DOI":"10.1055\/s-0037-1616068"},{"key":"66034","doi-asserted-by":"crossref","unstructured":"Rocco JM, Inglefield J, Yates B. Free interleukin-18 is elevated in CD22 CAR T-cell-associated hemophagocytic lymphohistiocytosis-like toxicities. Blood Adv. 2023; 7(20):6134-6139.","DOI":"10.1182\/bloodadvances.2023010708"},{"key":"66035","unstructured":"Marder VJ. Hemostasis and thrombosis: basic principles and clinical practice. 6th ed. Philadelphia. 2013;1566."},{"key":"66036","doi-asserted-by":"crossref","unstructured":"Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340(6):448-454.","DOI":"10.1056\/NEJM199902113400607"},{"key":"66037","doi-asserted-by":"crossref","unstructured":"Fish RJ, Neerman-Arbez M. Fibrinogen gene regulation. Thromb Haemost. 2012; 108(3):419-426.","DOI":"10.1160\/TH12-04-0273"},{"key":"66038","doi-asserted-by":"crossref","unstructured":"Carty CL, Heagerty P, Heckbert SR. Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the cardiovascular health study. Ann Hum Genet. 2010; 74(1):1-10.","DOI":"10.1111\/j.1469-1809.2009.00551.x"},{"key":"66039","doi-asserted-by":"crossref","unstructured":"Nishimoto N, Mima T. Tocilizumab. 2009;367-371.","DOI":"10.1016\/B978-032305475-1.50050-1"},{"key":"66040","doi-asserted-by":"crossref","unstructured":"He T, Ling J, Yang J. Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis. Sci Rep. 2023; 13(1):9050.","DOI":"10.1038\/s41598-023-36246-6"},{"key":"66041","doi-asserted-by":"crossref","unstructured":"Roumier M, Paule R, Vall\u00e9e A. Tocilizumab for severe worsening COVID-19 pneumonia: a propensity score analysis. J Clin Immunol. 2021; 41(2):303-314.","DOI":"10.1007\/s10875-020-00911-6"},{"key":"66042","doi-asserted-by":"crossref","unstructured":"\u00dcsk\u00fcdar Cansu D, Demirta\u015f E, Andi\u00e7 N, \u00dcsk\u00fcdar Teke H, Korkmaz C. Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review. Rheumatol Int. 2019; 39(4):743-750.","DOI":"10.1007\/s00296-019-04268-x"},{"key":"66043","doi-asserted-by":"crossref","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023; 141(20):2430-2442.","DOI":"10.1182\/blood.2022017414"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284564\/76835","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284564\/77435","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11522\/76835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:05Z","timestamp":1794045965000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284564","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,28]]}}}